Market closedNon-fractional
Neuropace/NPCE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Neuropace
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.
Ticker
NPCE
Sector
Healthcare
Trading on
NASDAQ
Industry
Health Care Equipment and Supplies
Headquarters
Mountain View, United States
Employees
181
Website
www.neuropace.com
Neuropace Metrics
BasicAdvanced
$234M
Market cap
-
P/E ratio
-$1.19
EPS
2.07
Beta
-
Dividend rate
Price and volume
Market cap
$234M
Beta
2.07
Financial strength
Current ratio
6.427
Quick ratio
5.383
Long term debt to equity
497.887
Total debt to equity
509.623
Interest coverage (TTM)
-3.00%
Management effectiveness
Return on assets (TTM)
-16.09%
Return on equity (TTM)
-150.63%
Valuation
Price to revenue (TTM)
3.133
Price to book
16.13
Price to tangible book (TTM)
16.13
Price to free cash flow (TTM)
-12.242
Growth
Revenue change (TTM)
42.07%
Earnings per share change (TTM)
-35.85%
3-year revenue growth (CAGR)
17.68%
3-year earnings per share growth (CAGR)
-78.41%
What the Analysts think about Neuropace
Analyst Ratings
Majority rating from 7 analysts.
Neuropace Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$18M
0.56%
Net income
-$8.9M
43.55%
Profit margin
-49.17%
42.77%
Neuropace Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.36
-$0.28
-$0.23
-$0.32
-
Expected
-$0.47
-$0.41
-$0.32
-$0.32
-$0.30
Surprise
-22.58%
-31.71%
-26.98%
-0.52%
-
Neuropace News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Neuropace stock?
Neuropace (NPCE) has a market cap of $234M as of July 27, 2024.
What is the P/E ratio for Neuropace stock?
The price to earnings (P/E) ratio for Neuropace (NPCE) stock is 0 as of July 27, 2024.
Does Neuropace stock pay dividends?
No, Neuropace (NPCE) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Neuropace dividend payment date?
Neuropace (NPCE) stock does not pay dividends to its shareholders.
What is the beta indicator for Neuropace?
Neuropace (NPCE) has a beta rating of 2.07. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Neuropace stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.